Jump to navigation

  • IHME
  • GHDx
  • GBD Compare
Home
Main menu
  • Home
  • Results
    • GBD Results Tool
    • Data Visualizations
    • Country Profiles
    • GBD 2019 Cause and Risk Summaries
    • US Health
    • Policy Reports
    • Research Articles
    • Infographics
    • Topics
    • Data & Tools
  • News & Events
    • News
    • Commentaries
    • Events
    • Videos
    • Acting on Data
      • IHME Foundations
  • Projects
    • COVID-19 resources
    • Global Burden of Disease (GBD)
    • Center for Health Trends and Forecasts (CHTF)
    • Disease Control Priorities Network (DCPN)
    • View all
  • Get Involved
    • Donate
    • Careers
    • Call for Collaborators
    • The Roux Prize
    • Murray-Lopez Award
    • Online Training
    • Courses
    • Degree programs
    • Workshops
  • About
    • Racism is a public health issue.
    • Our Principles
    • Faculty
    • Senior Management Team
    • Governance
    • History
    • GHDx
    • Terms and Conditions
    • Contact Us

Explore section

Results

  • GBD Results Tool
  • Data Visualizations
  • Country Profiles
  • GBD 2019 Cause and Risk Summaries
  • US Health
  • Policy Reports
  • Research Articles
  • Infographics
  • Topics
  • Data & Tools

Acute hepatitis A — Level 4 cause


Summary Acute hepatitis A resulted in 2·35 million (95% UI 1·70–3·09) global DALYs in 2019 and was responsible for 53·9% (42·9–63·6) of acute hepatitis DALYs.

Definition Hepatitis A is a viral infection that affects the liver. It is transmitted by faeco-oral route.

Total sources
Incidence 0
Prevalence 472
Remission 0
Causes of death 2581
Other 0
Table 1: Total sources used in GBD 2019 estimation
What is new in GBD 2019?
  • •Adjustments for seroprevalence data collected from blood donors, pregnant women, and exclusively vaccinated samples were estimated in MR-BRT prior to analysis in DisMod-MR 2.1. These adjustments corrected data toward the measurements we would expect if they had been collected in a general population sample.
  • •Acute hepatitis A mortality was modelled in CODEm rather than the natural history model of past GBD rounds, which had the effect of increasing estimates. This allowed us to drop the assumption that case fatality ratios estimated from hospital inpatient data can be applied to all symptomatic cases of acute hepatitis A occurring in the community.
Prevalence
Incidence
Deaths
YLLs
YLDs
DALYs
Cases
(millions)
Rate (per 100 000)
Cases
(millions)
Rate (per 100 000)
Deaths
(millions)
Rate (per 100 000)
YLLs
(millions)
Rate (per 100 000)
YLDs
(millions)
Rate (per 100 000)
DALYs
(millions)
Rate (per 100 000)
2019
Both Sexes
12·2
(11·5
to 13·0)
174·8
(163·2
to 186·3)
159
(149
to 169)
2272·1
(2121·8
to 2421·8)
0·0393
(0·0280
to 0·0524)
0·5
(0·4
to 0·7)
2·13
(1·49
to 2·89)
29·0
(20·1
to 39·5)
0·216
(0·138
to 0·316)
2·9
(1·8
to 4·2)
2·35
(1·70
to 3·09)
31·9
(23·0
to 42·4)
Females
5·95
(5·59
to 6·32)
175·0
(163·5
to 186·3)
77·3
(72·7
to 82·2)
2274·7
(2125·7
to 2421·7)
0·0182
(0·0107
to 0·0264)
0·5
(0·3
to 0·7)
0·986
(0·591
to 1·49)
27·4
(16·4
to 42·0)
0·105
(0·0672
to 0·152)
2·9
(1·8
to 4·2)
1·09
(0·686
to 1·60)
30·3
(19·1
to 44·8)
Males
6·28
(5·88
to 6·68)
174·6
(162·9
to 186·1)
81·6
(76·5
to 86·8)
2269·9
(2117·6
to 2419·4)
0·0211
(0·0149
to 0·0290)
0·6
(0·4
to 0·8)
1·15
(0·798
to 1·58)
30·7
(21·3
to 42·4)
0·111
(0·0705
to 0·165)
2·9
(1·8
to 4·3)
1·26
(0·899
to 1·70)
33·6
(23·9
to 45·7)
Percentage change 2010-19
Both Sexes
3·6%
(3·1
to 4·0)
–0·2%
(–0·7
to 0·3)
3·6%
(3·1
to 4·0)
–0·2%
(–0·7
to 0·3)
–39·8%
(–51·6
to –22·8)
–46·5%
(–57·3
to –30·8)
–48·5%
(–60·3
to –32·3)
–52·3%
(–63·5
to –36·8)
7·9%
(0·4
to 16·0)
1·9%
(–5·7
to 10·0)
–45·9%
(–57·3
to –30·1)
–49·9%
(–60·9
to –34·8)
Females
3·6%
(3·0
to 4·1)
–0·2%
(–0·8
to 0·4)
3·6%
(3·0
to 4·1)
–0·2%
(–0·8
to 0·4)
–43·5%
(–55·9
to –17·0)
–50·3%
(–61·5
to –26·4)
–52·6%
(–64·7
to –28·9)
–56·4%
(–68·0
to –34·1)
7·8%
(–2·5
to 19·1)
1·9%
(–8·8
to 13·6)
–49·9%
(–61·8
to –27·5)
–53·9%
(–65·0
to –32·6)
Males
3·5%
(3·0
to 4·1)
–0·1%
(–0·8
to 0·4)
3·5%
(3·0
to 4·1)
–0·1%
(–0·8
to 0·4)
–36·3%
(–50·9
to –18·6)
–42·9%
(–56·0
to –27·3)
–44·3%
(–58·3
to –28·6)
–48·2%
(–61·6
to –32·7)
7·9%
(–2·7
to 19·5)
1·9%
(–8·7
to 13·5)
–41·8%
(–55·2
to –26·3)
–45·9%
(–58·7
to –30·9)
Numbers in parentheses are 95% uncertainty intervals.
Table 2: Global prevalence, incidence, deaths, YLLs, YLDs, and DALYs in counts and age-standardised rates for both sexes combined, females, and males, 2019, with percentage change between 2010 and 2019
Deaths YLLs YLDs DALYs
1990 72nd 57th 182nd 73rd
2010 107th 81st 181st 114th
2019 132nd 114th 185th 161st
Table 3: Rank among most detailed causes for global deaths, YLLs, YLDs, and DALYs in 1990, 2010, and 2019, for both sexes combined
Figure 1: Composition of DALYs by YLLs and constituent sequelae YLDs for both sexes combined, 2019
No Legend
Figure 2: Age-standardised DALY rates for each location by SDI, both sexes combined, 2019
Figure 3: Composition of DALYs by YLLs and YLDs, age group, and sex, 2019
No Legend
Figure 4: Age-standardised DALY rates (per 100 000) by location, both sexes combined, 2019

Results

  • GBD Results Tool
  • Data Visualizations
  • Country Profiles
  • GBD 2019 Cause and Risk Summaries
  • US Health
  • Policy Reports
  • Research Articles
  • Infographics
  • Topics
  • Data & Tools

Stay connected

     

IHME

Institute for Health Metrics and Evaluation

Population Health Building/Hans Rosling Center

3980 15th Ave. NE, Seattle, WA 98195

UW Campus Box #351615

Tel: +1-206-897-2800

Fax: +1-206-897-2899

© 2020 University of Washington

  • Privacy policy
  • Login

  • Home
  • Results
    • GBD Results Tool
    • Data Visualizations
    • Country Profiles
    • GBD 2019 Cause and Risk Summaries
    • US Health
    • Policy Reports
    • Research Articles
    • Infographics
    • Topics
    • Data & Tools
  • News & Events
    • News
    • Commentaries
    • Events
    • Videos
    • Acting on Data
  • Projects
    • COVID-19 resources
    • Global Burden of Disease (GBD)
    • Center for Health Trends and Forecasts (CHTF)
    • Disease Control Priorities Network (DCPN)
    • View all
  • Get Involved
    • Donate
    • Careers
    • Call for Collaborators
    • The Roux Prize
    • Murray-Lopez Award
    • Online Training
    • Courses
    • Degree programs
    • Workshops
  • About
    • Racism is a public health issue.
    • Our Principles
    • Faculty
    • Senior Management Team
    • Governance
    • History
    • GHDx
    • Terms and Conditions
    • Contact Us

Projects

  • Global Burden of Disease (GBD)
  • Disease Control Priorities Network (DCPN)
  • ABCE+: A Focus on Antiretroviral Therapy (ART)
  • Access, Bottlenecks, Costs, and Equity (ABCE)
  • Efficacy to Effectiveness
  • Viral Load Pilot
  • Salud Mesoamérica Initiative
  • Improving Methods to Measure Comparable Mortality by Cause
  • Verbal Autopsy (VA)
  • Disease Expenditure (DEX)
  • Local Burden of Disease
  • State-level disease burden initiative in India
  • US Counties Drivers of Health Study
  • University of Washington Center for Health Trends and Forecasts